"Exploring benefits of L-carnitine in hemodialysis: promising findings await clinical application".

L-carnitine, a crucial component in the metabolism of fatty acids, has shown promise as a treatment for malnutrition and cardiovascular disease in hemodialysis patients. The 2025 meta-analysis by Nabi et al., which documented a statistically significant improvement in left-ventricular ejection fraction (LVEF) after L-carnitine supplementation, is the focus of this letter's evaluation of previous data. Although there has been a noticeable increase in systolic performance, there are still conflicting data on diastolic function and left-ventricular mass index (LVMI). Furthermore, it is becoming more widely acknowledged that L-carnitine deficit contributes to malnutrition in patients on maintenance hemodialysis. This highlights the need for thorough, high-quality clinical trials to confirm the therapeutic efficacy of L-carnitine and evaluate its influence on long-term clinical outcomes.